A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data.
This study compared the cost and effectiveness of highly purified, human-derived follicle-stimulating hormone (FSH) (Bravelle) to recombinant FSH (Follistim) using Markov modeling and Monte Carlo simulation. One IVF treatment cycle resulted in costs of 11,584 dollars +/- 211 dollars for human-derived FSH and 12,762 dollars +/- 170 dollars for recombinant FSH, while three treatment cycles, holding the transition probabilities of the first cycle constant for the next two cycles, resulted in costs of 22,712 dollars +/- 1,107 dollars for human-derived FSH and 24,935 dollars +/- 1,205 dollars for recombinant FSH.
Hatoum
Hind T
HT
Hind T. Hatoum and Company, Chicago, Illinois, USA.
Keye
William R
WR
Marrs
Richard P
RP
Walton
Surrey M
SM
Marshall
Dennis C
DC
D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D005260:Female; D005307:Fertilization in Vitro / Q000191:economics*; D005640:Follicle Stimulating Hormone / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D008390:Markov Chains; D017059:Models, Econometric; D009010:Monte Carlo Method; D011247:Pregnancy; D011994:Recombinant Proteins / Q000191:economics* / Q000627:therapeutic use
D011994:Recombinant Proteins; D005640:Follicle Stimulating Hormone